In this presentation, we will talk about diagnosis of bacteria and chronic …
In this presentation, we will talk about diagnosis of bacteria and chronic infections in clinical practices. We will discuss why we need to diagnose bacteria in infections and what the biggest challenges are in diagnosing bacterial and chronic infections. Finally, we will discuss what the future will bring, regarding bacteria and diagnosis.
Pharmacology Notes: Nursing Implications for Clinical Practice is intended to organize pharmacological …
Pharmacology Notes: Nursing Implications for Clinical Practice is intended to organize pharmacological information in a meaningful manner that draws from prior learning (i.e. anatomy & physiology and pathophysiology), in order to reveal and reinforce relevant nursing implications. These notes utilize the framework, A-T-A-T, to assist in understanding nursing implications related to medication administration.
This resource is a video abstract of a research paper created by …
This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"Kidney transplant patients currently require life-long treatment with immunosuppressive drugs to prevent their body from rejecting the transplanted organ. Immunosuppression can have side effects such as an increased risk of infections or developing comorbidities such as new onset diabetes or certain malignancies. Other side effects are related to the drugs’ toxicity, such as kidney damage, ultimately leading to a return to dialysis or need for re-transplant. A clinical trial, TRANSFORM, was carried out to test a new immunosuppressive regimen consisting of everolimus plus low-dose CNI, versus the current standard-of-care regimen: mycophenolic acid plus the standard, higher dose of CNI. The two-year results of this trial showed that the combination of everolimus plus low CNI had a similar ability to prevent kidney rejection or severe kidney impairment as the current standard-of-care regimen..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
No restrictions on your remixing, redistributing, or making derivative works. Give credit to the author, as required.
Your remixing, redistributing, or making derivatives works comes with some restrictions, including how it is shared.
Your redistributing comes with some restrictions. Do not remix or make derivative works.
Most restrictive license type. Prohibits most uses, sharing, and any changes.
Copyrighted materials, available under Fair Use and the TEACH Act for US-based educators, or other custom arrangements. Go to the resource provider to see their individual restrictions.
